# Duchenne muscular dystrophy

Type: Technology

Source: GetYourBrief — https://getyourbrief.com/entity/duchenne-muscular-dystrophy
Canonical HTML page: https://getyourbrief.com/entity/duchenne-muscular-dystrophy

## Timeline

- **2026-03-11**: Document Request — Expected date for formal requests for internal FDA communications regarding DMD drug applications.
- **2026-03-11**: Initial Inquiry — The Senator's office begins requesting data on DMD drug approval timelines and internal CBER deliberations.
- **2026-03-10**: Investigation Announced — Sen. Ron Johnson publicly declares a formal inquiry into the FDA's rare disease drug approval process.
- **2026-03-10**: Commissioner Consultation — Johnson speaks with FDA Commissioner Marty Makary to discuss specific drug rejections and agency policy.
- **2026-03-10**: Investigation Announced — Sen. Ron Johnson announces a formal probe into the FDA's handling of rare disease drug applications.
- **2026-03-10**: Commissioner Meeting — Johnson meets with FDA Commissioner Marty Makary to discuss specific biologic therapy rejections.

## Recent coverage (3 stories, network-wide)

### GOP Senator Probes FDA Over Rare Disease Drug Rejections
2026-03-10 22:18:47 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Senator Ron Johnson (R-Wisc.) has launched an investigation into the FDA's regulatory hurdles for rare disease treatments, specifically targeting biologics for Duchenne muscular dystrophy. The probe follows a direct meeting with FDA Commissioner Marty Makary and signals a significant escalation in political pressure on the agency's approval standards.
Full story: https://getbiobrief.com/story/ron-johnson-fda-rare-disease-investigation

### Senator Ron Johnson Launches Investigation Into FDA Rare Disease Drug Denials
2026-03-10 22:18:15 · Sector: health · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA's handling of biologic therapy applications for rare diseases, specifically targeting Duchenne muscular dystrophy. The probe follows a direct consultation with FDA Commissioner Marty Makary regarding perceived regulatory barriers for life-saving treatments.
Full story: https://gethealthbrief.com/story/ron-johnson-fda-rare-disease-investigation

### Senator Johnson Launches Investigation into FDA Rare Disease Drug Denials
2026-03-10 22:17:42 · Sector: legal · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA’s regulatory processes regarding the rejection of biologic therapies for Duchenne muscular dystrophy and other rare diseases. The probe follows high-level discussions with FDA Commissioner Marty Makary and focuses on whether the agency's evidentiary standards are too restrictive for life-threatening conditions.
Full story: https://getlegalbrief.com/story/senator-johnson-fda-rare-disease-investigation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.